In the present study, 1 single-dose and 1 multiple-dose models were applied in studying 4'-iodo-4'deoxydoxorubicin (I-DX) cardiotoxicity. Anthracycline cardiotoxicity has been reproduced in several animals including mice, rats, hamsters, rabbits, dogs, and monkeys. Of these species, the rat can be considered the most suitable species for the study of anthracycline-induced cardiomyopathy. The cardiotoxicity induced by I-DX in male Sprague-Dawley rats was compared to that of doxorubicin (DX), used as standard positive control. Groups of 3 6 4 2 rats were given single or repeated doses of the compounds, injected intravenously in a volume of 5.0 mVkg. Animals were observed for up to 35 wk to follow the progression of the lesions.
INTRODUCTION
Anthracycline compounds induce a chronic doselimiting cardiomyopathy characterized by cardiac dilation and myocyte degeneration to the point of congestive heart failure. Human cardiomyopathy has been reproduced in several animal species including mice, rats, hamsters, rabbits, dogs, and monkeys (1, 3, 5-7), and it has been demonstrated that in all species the incidence and severity of myocardial damage is clearly dose-dependent and related to the single or cumulative dose administered (10) . 4'-Iodo-4'-deoxydoxorubicin (I-DX) is a doxorubicin (DX) derivative containing an iodine atom in position 4' of the aminosugar moiety ( Fig. 1 ) that has been synthesized in an attempt to lessen the toxic effects of the parent compound and enhance its antitumor spectrum to include hitherto unresponsive tumors (2) . The purpose of these studies was to compare the cardiotoxicity of I-DX with that of DX in the single-and multiple-dose cardiotoxicity regimens in * Address correspondence to: Arturo PodestA, Farmitalia Carlo Erba S.p.A., Via Giovanni XXIII, 23, 20014 Nerviano, Italy. rats expressly devised in our laboratories for anthracyclines.
MATERIALS AND METHODS
In the single-dose study, groups of 42 male Sprague-Dawley rats, about 7 wk old and weighing 170-2 19 g when treated, were given iv a single injection of I-DX at the doses of 3.0,4.5, and 6.0 mg/ kg or DX at the doses of 3.0 and 6.0 mg/kg. The compounds, dissolved in normal saline, were administered via tail veins in a volume of 5 mYkg at an approximate injection rate of 3 ml/min. In the repeated-dose study, groups of 36 male rats, as already described, were given 1.00, 1.50, and 2.25 the time course of the lesions. In the single-dose study, a further sacrifice was performed in week 2.
All animals, sacrificed by bleeding from the abdominal aorta under Farmotal i.p. anesthesia, were necropsied, heart and kidney weights were recorded, and the hearts were processed for histological examination.
Hearts were fixed in 4% buffered paraformaldehyde, embedded in plastic, semithin-sectioned (approximately 1 pm), and stained with Toluidine blue. Cardiomyopathy was evaluated by grading the severity and extent of the myocardial lesions on a qualitative/quantitative scale expressly devised for anthracyclines (10) .
In particular, the scheme used was as follows: The product of the severity score multiplied by the extent score was the total cardiotoxicity score for each animal, from which the mean total score (MTS) for the various experimental groups was calculated:
Severity (s)
The MTS of I-DX-treated groups were statistically compared to those of the positive control (DX) by Kruskal-Wallis and Dunn's test (4, 9) , taking into account the scores obtained in the left ventricle and septum at the time in which the highest MTS had been reached.
RFSULTS

Single-Dose St iidy
In this experiment, I-DX proved to be only slightly toxic even at the highest dose tested. The compound did not induce mortality, organ weight changes, or kidney lesions. At the 2 highest doses, slight but statistically significant decreases in body weight gain were noted together with gross changes in some lymphoid and reproductive organs. On the basis of clinical signs, body weight changes, and gross and histological findings, the toxicity induced by 6.0 mg/kg I-DX was comparable to that induced by 3.0 mg/kg DX.
The parent compound, at the standard doses of 3.0 and 6.0 mg/kg, induced clear cardiotoxicity with a dose-related and time-related trend starting from weeks 4 and 2, respectively.
With both DX doses, the peak was reached in week 12, when moderate and marked myocardial lesions were detected (MTS 2.00 at 3.0 mg/kg and 4.33 at 6.0 mg/kg). Histological examination of the heart of the animals treated with I-DX revealed slight sporadic myocardial lesions similar to those already described only at 6.0 mg/kg. The maximum MTS (0.33) was reached in week 35 (Fig. 2) 
Repeated-Dose Study
No noticeable toxicity was recorded at 1 .OO mg/ (Fig. 3 ). The differences in cardiotoxicity between 1.00 and 1.50 mg/kg/wk of I-DX and the same doses of DX were always statistically significant (p I . 0.0 1).
DISCUSSION
The rat has been established as an accurate, reproducible, and cost-effective system for testing anthracycline-induced cardiotoxicity (8, 1 1). Utilizing this species, 2 distinct models or assays have been developed. One is based on a single-dose and the b second on a multiple-dose regimen. The duration of both experiments is 35 wk. Interim sacrifices at 4, 8, 12, 22, 27 , and 35 weeks were very helpful in monitoring the progression of the cardiomyopathy, thus mimicking the transvenous endomyocardial biopsy of humans. The threshold of irreversibility of the DX-induced cardiomyopathy was shown to be lowest in rat at 27 mg/m2, followed by 58 mg/ m2 in the mouse, 70 mg/m2 in the rabbit, approximately 84 mg/mz in the monkey, and approximately 135 mg/mz in the dog (6) . When expressed in mg/kg, the rat still has the lowest threshold value at 3.8 mg/kg. This value is also the closest to the human value at 4.6 mg/kg. Therefore, the value of extrapolation to humans is substantial. As expected, both dosing regimens (single and multiple) of DX induced moderate to marked time-and dose-related myocyte vacuolar degeneration, starting from weeks 2-4 and 4-8, respectively. In both experimental models, I-DX proved to be less cardiotoxic than DX, and the differences were frequently statistically significant. If the cardiotoxicity induced by single or repeated equitoxic doses ofthe 2 compounds (6.0 mg/kg I-DX vs 3.0 mg/kg DX and 2.25 mg/kg/week I-DX vs 1.00 mg/kg/week DX) is compared, the myocardial damage induced by the new derivative appears to be about 80 and 70% less severe, respectively, than that induced by DX. Clinical trials seem to confirm that both experimental models can be considered a great aid in predicting results in human therapeutic situations. However, the multiple-dose regimen seems to be more suitable for detecting and evaluating the myocardial damage induced by compounds like I-DX, which possess a low cardiotoxic potential and which could go undetected with the single-dose regimen.
